Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation

Hepatology

Volumn 30, Issue 1, 1999, Pages 244-256

  Tillmann, Hans L ^a   Trautwein, Christian ^a   Bock, Thomas ^a   Böker, Klaus H W ^a   Jäckel, Elmar ^a   Glowienka, Medea ^a   Oldhafer, Karl ^a   Bruns, Insa ^b   Gauthier, Josee ^b   Condreay, Lynn D ^b   Raab, Hans Rudolf ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; FAMCICLOVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; LAMIVUDINE; VIRUS DNA;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DNA SEQUENCE; DRUG TOLERABILITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECURRENT INFECTION; REINFECTION; STRUCTURAL GENE; TREATMENT FAILURE; VIRUS GENE; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

2-AMINOPURINE; ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; DNA PRIMERS; DNA-DIRECTED DNA POLYMERASE; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; MALE; METHIONINE; MIDDLE AGED; POINT MUTATION; POLYMERASE CHAIN REACTION; PRODRUGS; RECURRENCE; RISK FACTORS; VALINE;

EID: 0033067529     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300141     Document Type: Article

References (28)

1. Belle SH, Beringer KC, Detre KM: An update on liver transplantation in the United States: recipient characteristics and outcome. Clin Transpl 1995;19-33.
2. O'Grady JG, Smith HM, Davies SE, Daniels HM, Donaldson PT, Tan KC, Portmann B, et al. Hepatitis B virus reinfection after orthotopic liver transplantation: serological and clinical implications. J Hepatol 1992;14:104-111.
3. Todo S, Demetris AJ, Van Thiel D, Taperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. HEPATOLOGY 1991;13:619-626.
4. Samuel D, Müller R, Alexander G, Fassati L, Ducot B, Benhamou JP, Bismuth H. Liver transplantation in European patients with hepatitis B surface antigen. N Engl J Med 1993;329:1842-1847.
5. Müller R, Gubernatis G, Farle M, Niehoff G, Klein H, Wittekind C, Tusch G, et al. Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991;13:90-96.
6. Trautwein C, Schrem H, Tillmann HL, Kubicka S, Walker D, Böker KHW, Maschek HJ, et al. Hepatitis B virus mutations in the pre-S genome before and after liver transplantation. HEPATOLOGY 1996;24:482-488.
7. Tsiquaye KN, Slomka MJ, Maung M. Oral famciclovir against duck hepatitis B virus replication in hepatic and nonhepatic tissue of ducklings infected in ovo. J Med Virol 1994;42:306-310.
8. Doong SL, Tsai CH, Schinazi RF, Liotta DC, Cheng YC. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-8499.
9. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trail of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:2657-1661.
10. Böker KH, Ringe B, Krüger M, Pichlmayr R, Manns MR Prostaglandin E plus famciclovir - a new concept for the treatment of severe hepatitis B after liver transplantation. Transplantation 1994;57:1706-1708.
11. Lin E, Luscombe C, Wang Y, Shaw S, Locarnini S. The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother 1996;40:413-418.
12. Offensperger WB, Offensperger S, Keppler-Hafkemeyer A, Hafkemeyer P, Blum HE. Antiviral activities of penciclovir and famciclovir on duck hepatitis B virus in vitro and in vivo. Antiviral Ther 1996;1:141-146.
13. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A 1993;90:5653-5656.
14. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymease during therapy of transplant recipients with lamivudine. HEPATOLOGY 1996;24:711-713.
15. Bartholomow MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
16. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL: Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996;24:714-717.
17. Tipples GA, Ma MM, Fischer KP, Gutfreund KS, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV-RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996;24(Supp 1):283A.
18. Hankoop P, Niesters HGM, de Man RAM, Osterhaus ADME, Schalm S: Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol 1997;26:1393-1395.
19. De Man RA, Bartholomeusz A, Locarnini S, Niesters HGM, Zondervan PE. The occurrence of sequential viral mutations in a liver transplant recipient re-infected with hepatitis B: primary famciclovir resistance followed by a lethal hepatitis during acquired lamivudine resistance. J Hepatol 1997;26(Supp 1):77.
20. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P, et al. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J Hepatol 1997;26:1148-1153.
21. Aye TT, Bartholomeusz AI, Shaw T, Breschkin AM, Gronen L, Bowden DS, McMillan J, et al. Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation. HEPATOLOGY 1996;24(Suppl):285A.
22. Naoumov NV, Chokshi S, Smith H, Williams R. Emergence and Characterisation of lamivudine resistant hepatitis B virus variant. HEPATOLOGY 1996;24:282A.
23. Neuhaus P, Manns M, Atkinson G on behalf of the FCV liver transplant group. Safety and efficacy of famciclovir for the treatment of recurrent hepatitis B in liver transplant recipients. HEPATOLOGY 1997;26:A260.
24. Tillmann H, Trautwein C, Walker D, Michitaka K, Kubicka S, Böker K, Manns M. Clinical relevance of mutations in the precore genome of the hepatitis B virus. Gut 1995;57:1588-1593.
25. Michitaka K, Durazzo M, Tillmann HL, Walker D, Philipp T, Manns MP. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 1994;106:1603-1610.
26. Bartholomeusz A, Locarnini S. Mutations in hepatitis B virus polymerase gene associated with famciclovir and lamivudine. International Antiviral News 1997;5:123-124.
27. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in Escherichia coli. Nature 1979;281:646-650.
28. Valenzuel P, Quiroga M, Zaldivar J, Gray P, Rutter W. The nucleotide sequence of the hepatitis B genome and the identification of the major viral genes. In: Fields B, Jaenisch R, Fox C, eds. Animal Virus Genetics. New York: Academic Press, 1980:57-70.